News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
ORBIMED ADVISORS LLC
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/24/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 05/24/2023 |
SC 13D
| ORBIMED ADVISORS LLC reports a 7.7% stake in VectivBio Holding AG |
| 03/31/2023 |
SC 13D
| ORBIMED ADVISORS LLC reports a 11.2% stake in Gracell Biotechnologies Inc. |
| 02/28/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 09/28/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 10/19/2021 |
SC 13D
| ORBIMED ADVISORS LLC reports a 44.9% stake in Theseus Pharmaceuticals, Inc. |
| 06/21/2021 |
SC 13D
| ORBIMED ADVISORS LLC reports a 7.3% stake in Janux Therapeutics, Inc. |
| 04/14/2021 |
SC 13D
| ORBIMED ADVISORS LLC reports a 6.6% stake in Ikena Oncology, Inc. |
| 04/07/2021 |
SC 13D
| ORBIMED ADVISORS LLC reports a 27.8% stake in Edgewise Therapeutics, Inc. |
| 03/01/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/22/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/22/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 01/21/2021 |
SC 13D
| ORBIMED ADVISORS LLC reports a 9.1% stake in Gracell Biotechnologies Inc. |
| 12/11/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 22.4% stake in Silverback Therapeutics, Inc. |
| 12/11/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 7.8% stake in Kinnate Biopharma Inc. |
| 11/06/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 11.3% stake in Galecto, Inc. |
| 10/05/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 10/05/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 10/05/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 08/18/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 07/06/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 7.2% stake in Fusion Pharmaceuticals Inc. |
| 06/29/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 24.4% stake in Compass Therapeutics, Inc. |
| 06/25/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 05/01/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 9.2% stake in ORIC Pharmaceuticals, Inc. |
| 04/17/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 6.3% stake in Keros Therapeutics, Inc. |
| 03/20/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 15.3% stake in IMARA Inc. |
| 03/09/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/10/2020 |
SC 13D
| ORBIMED ADVISORS LLC reports a 10.7% stake in Arcutis Biotherapeutics, Inc. |
| 11/25/2019 |
SC 13D
| ORBIMED ADVISORS LLC reports a 27.7% stake in TELA Bio, Inc. |
| 11/25/2019 |
SC 13D
| ORBIMED ADVISORS LLC reports a 15.4% stake in 89bio, Inc. |
| 09/25/2019 |
SC 13D
| ORBIMED ADVISORS LLC reports a 17.1% stake in SpringWorks Therapeutics, Inc. |
| 09/18/2019 |
SC 13D
| ORBIMED ADVISORS LLC reports a 8.9% stake in Bellus Health Inc. |
| 06/27/2019 |
SC 13D
| ORBIMED ADVISORS LLC reports a 40.7% stake in Prevail Therapeutics Inc. |
| 05/21/2019 |
SC 13D
| ORBIMED ADVISORS LLC reports a 8.4% stake in NextCure, Inc. |
|
|
|